Rituximab therapy in chronic inflammatory demyelinating polyradiculoneuropathy with anti-SGPG IgM antibody.

Authors :: Gono T
Matsuda M
Shimojima Y
Ishii W
Yamamoto K
Morita H
Hashimoto T
Susuki K
Yuki N
Ikeda S
Source :: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia [J Clin Neurosci] 2006 Jul; Vol. 13 (6), pp. 683-7. Date of Electronic Publication: 2006 Jun 30.
Publication Year :: 2006
Abstract: We report a patient with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who showed high titers of anti-sulfated glucuronyl paragloboside (SGPG) IgM antibody without M-protein in serum. The patient was resistant to corticosteroids and immunosuppressants, but after administration of rituximab, clinical symptoms improved and the patient remained in a stable state for approximately 10 months. Rituximab may be a potent therapeutic option for refractory cases of CIDP irrespective of detectable M-protein in either serum or urine.

Subjects :: Adult
Antibodies, Monoclonal, Murine-Derived
Drug Therapy, Combination
Follow-Up Studies
Humans
Male
Neural Conduction drug effects
Neural Conduction physiology
Neural Conduction radiation effects
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating physiopathology
Reaction Time drug effects
Reaction Time radiation effects
Rituximab
Antibodies, Monoclonal therapeutic use
Antirheumatic Agents therapeutic use
Globosides immunology
Immunoglobulin M therapeutic use
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating drug therapy

Language :: English
ISSN :: 0967-5868
Volume :: 13
Issue :: 6
Database :: MEDLINE
Journal :: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
Publication Type :: Academic Journal
Accession number :: 16814550
Full Text :: https://doi.org/10.1016/j.jocn.2005.09.008

Full Text Access

Tools